Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Mount Sinai School of Medicine
Sponsor:
Collaborators:
Myeloproliferative Disorders-Research Consortium
Roche Pharma AG
QIAGEN Marseille
Information provided by (Responsible Party):
Ronald Hoffman, Mount Sinai School of Medicine
ClinicalTrials.gov Identifier:
NCT01259856
First received: December 7, 2010
Last updated: June 11, 2014
Last verified: June 2014
  Purpose

This research is looking at two conditions, Essential Thrombocythemia (ET) and Polycythemia Vera (PV). ET causes people to produce too many blood cells called platelets and PV causes too many platelets and red blood cells to be made. Platelets are particles which circulate in the blood stream and normally prevent bleeding and bruising. Having too many platelets in the blood increases the risk of developing blood clots, which can result in life threatening events like heart attacks and strokes. When the number of red blood cells is increased in PV this will slow the speed of blood flow in the body and increases the risk of developing blood clots.

The purpose of this study is to look at the effectiveness of giving participants who have been diagnosed with ET or PV one of two different study regimens over time. The study subject will be followed for their condition for about 5 years. The subject will be randomized into one of two study regimens, either Pegylated Interferon Alfa-2a (PEGASYS) or Aspirin and Hydroxyurea (also called Hydroxycarbamide). The subject must be newly diagnosed or already receiving treatment for either PV or ET. Each of the study drugs used in this study is already being used to treat subjects with ET or PV currently, but the investigators are unsure which study drug is better.


Condition Intervention Phase
High Risk Polycythemia Vera
High Risk Essential Thrombocythemia
Drug: PEGASYS
Drug: Hydroxyurea
Drug: Aspirin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Resource links provided by NLM:


Further study details as provided by Mount Sinai School of Medicine:

Primary Outcome Measures:
  • To compare hematologic response rates in patients randomized to treatment with Pegylated Interferon Alfa-2a vs Hydroxyurea in two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To compare the toxicity, safety and tolerability of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) in the study populations by recording the adverse events that occur during the study using the CTC 4.0 as the guide. [ Time Frame: 4 ] [ Designated as safety issue: Yes ]
  • To compare the hematologic partial response rates on therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea). [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • To compare specific pre-defined toxicity and tolerance of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) and validate the utility of sequential structured symptom assessment package of patient reported outcome instruments. [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
    Improvement in disease symptoms will be measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) instrument being used in this study.

  • To compare the impact of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) on key biomarkers of the disease(s) by measuring the JAK2 allele burden. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • To compare the impact of therapy on JAK2-V617F (JAK2), hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    The impact of PEGASYS on JAK2 will be measured by the allele burden; hematopoietic cell clonality will be measured by whether patients with clonal disease return to polyclonal; bone marrow histopathology will be measured by going from abnormal to normal; cytogenetic abnormalities will be measured by seeing if the cytogenetics go from abnormal to normal.

  • To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea). [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    We plan to capture the rate of progression to a more advanced myeloid malignancy.

  • To estimate incidence of major cardiovascular events after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea). [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
    Capture and record the cardiovascular events that occur during the study.


Estimated Enrollment: 612
Study Start Date: September 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PEGASYS
The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
Drug: PEGASYS
The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
Other Name: Pegylated Interferon Alfa-2a
Drug: Aspirin
Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
Other Name: acetylsalicylic acid
Active Comparator: Hydroxyurea
Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
Drug: Hydroxyurea
Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
Other Name: Hydroxycarbamide
Drug: Aspirin
Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
Other Name: acetylsalicylic acid

Detailed Description:

The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) are a group of clonal hematological malignancies that are characterized by a chronic course which can be punctuated by a number of disease related events including thrombosis, hemorrhage, pruritis and leukemic transformation. These disorders include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PM). Recently an acquired somatic mutation in the intracellular kinase, JAK2 (JAK2V617F) has been observed in 95% of patients with PV, 50% of patients with ET and 50% of patients with primary myelofibrosis. At present the chemotherapeutic agent hydroxyurea is the standard of care for high risk patients with PV. Concern exists about prolonged use of this drug leading to leukemia and the inability of hydroxyurea to eliminate the malignant clone.

Interferon (rIFN -2b), is a drug that appears to be non-leukemogenic, and may have a preferential activity on the malignant clone in PV, as suggested by cytogenetic remissions obtained in patients treated with rIFN -2b. Several investigators recently reported that patients with PV treated with rIFN -2b had lower JAK2V617F allele burdens as compared to a control group that included patients treated with phlebotomy, hydroxyurea, or anagrelide, or who remained untreated. The results confirm the hypothesis that rIFN -2b preferentially targets the malignant clone in PV and raises the possibility that the JAK2V617F allele burden, and a reversion of clonal hematopoiesis monitored in females by expression of X-chromosome polymorphic alleles maybe useful in monitoring minimal residual disease in PV patients.

Pegylated Interferon Alfa-2a (PEGASYS) has been demonstrated in phase II trials of patients with PV and ET to have clinical efficacy as measured by normalization of myeloproliferation, lack of vascular events while on therapy, and a decrease in the JAK2V617F allele burden. Overall the tolerability of the therapy was good, with each of these trials having a dropout rate secondary to toxicity of less than 10% of those enrolled. Although dropout rates for toxicity were low, that is not to say the therapy was without symptomatic toxicity, and indeed a spectrum of toxicities might be encountered and need to be weighed in the analysis of the net clinical benefit patients experience on a clinical trial with Pegylated Interferon Alfa-2a.

A new MPN assessment form will be utilized in this study. This 19 item instrument includes a previously validated 9 item brief fatigue inventory (BFI), symptoms related to splenomegaly, inactivity, cough, night sweats, pruritus, bone pains, fevers, weight loss, and an overall quality of life assessment. The instrument yields an independent result for each symptom (fatigue is a composite score), as this methodology (of linear analog scale assessment [LASA]) has proven very valid in the past. This instrument was validated prospectively (by comparison to a panel of instruments each containing an aspect of the MPN-SAF) for administration at a single time point.

This is a randomized trial between hydroxyurea and Pegylated Interferon Alfa-2a, it is an open label clinical trial in two independent disease strata: (1) high risk polycythemia vera and (2) high risk essential thrombocythemia.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A diagnosis of Essential Thrombocythemia (ET) or Polycythemia Vera (PV) shall be made in accordance with the WHO (2008)criteria (Swerdlow 2008) as shown below.
  • Diagnosis < 3 years prior to entry.
  • Polycythemia Vera (2 major criteria required)

    1. Hb >18.5g/dl (♂) or 16.5g/dl (♀) or HCT >99 percentile reference range or Elevated red cell mass (>25% above mean predicted value) or Hb >17g/dl (♂) or 15g/dl (♀) if associated with a sustained rise from baseline with no apparent cause (e.g. treated iron deficiency).
    2. Presence of JAK2V617F
  • Essential Thrombocythemia (all 6 criteria required)

    1. Platelets count ≥ 450 x 10 to 9/L
    2. Megakaryocyte proliferation with large and mature morphology. No significant increase or left shift of neutrophil granulopoiesis or erythropoiesis. Patients may have up to and including 2+ marrow reticulin fibrosis (0, 1 or 2 on scale 0 -4).
    3. Not meeting WHO criteria for CML, PV, MDS, PMF or other myeloid neoplasm
    4. Demonstration of clonal cytogenetic marker or no evidence of reactive thrombocytosis.
    5. Absence of a leukoerythroblastic blood picture.
    6. May participate in study without presence of JAK2V617F.

      Patients must have high risk disease as defined below:

      High risk PV ANY ONE of the following:

      • Age ≥ 60 years
      • Previous documented thrombosis, erythromelalgia or migraine (severe, recurrent, requiring medications, and felt to be secondary to the MPN) either after diagnosis or within 10 years before diagnosis and considered to be disease related
      • Significant splenomegaly (> 5cm below the left costal margin on palpitation) or symptomatic splenomegaly (splenic infarcts or requiring analgesia)
      • Platelets > 1000 x 10 to 9/L
      • Diabetes or hypertension requiring pharmacological therapy for > 6 months

      High risk ET ANY ONE of the following:

      • Age ≥ 60 years
      • Platelet count > 1500 x 10 to 9/L
      • Previous documented thrombosis, erythromelalgia or migraine headaches (severe, recurrent, requiring medications, and felt to be secondary to the MPN) either after diagnosis or within 10 years before diagnosis and considered to be disease related
      • Previous hemorrhage related to ET
      • Diabetes or hypertension requiring pharmacological therapy for > 6 months

      Other Inclusion criteria (Both Strata)

      • Diagnosed less than 3 years prior to entry on trial
      • Never treated with cytoreductive drugs except hydroxyurea for up to 3 months maximum (phlebotomy, aspirin allowed, anagrelide allowed)
      • Age: > 18 years (no upper limit)
      • Ability and willingness to comply with all study requirements
      • Signed informed consent to participate in this study.
      • Willing to participate in associated correlative science biomarker study
      • Serum creatinine ≤ 1.5 x upper limit of normal
      • ST and ALT ≤ 2 x upper limit of normal
      • No known PNH (paroxysmal nocturnal hemoglobinuria) clone
      • No concurrent hormonal oral contraceptive use

      Exclusion Criteria:

      (ANY of the following, both strata)

      • Known to meet the criteria for primary myelofibrosis (as opposed to ET) by WHO 2008
      • Any contraindications to pegylated interferon or hydroxyurea
      • Presence of any life-threatening co-morbidity
      • History of active substance or alcohol abuse within the last year
      • Subjects who are pregnant, lactating or of reproductive potential and not practicing an effective means of contraception
      • History of psychiatric disorder (e.g. depression) Subjects with a history of mild depression may be considered for entry into this study, provided that a pretreatment assessment of the subject's affective status supports that the subject is clinically stable based on the investigator's normal practice for such subject.
      • History of autoimmune disorder (e.g. hepatitis)
      • Hypersensitivity to interferon alfa
      • Hepatitis B or C infection (HBV), or untreated systemic infection
      • Known HIV disease
      • Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration) or clinically relevant ophthalmological disorder (e.g. due to diabetes mellitus or hypertension)
      • History or other evidence of decompensated liver disease
      • Splanchnic vein thrombosis (includes Budd-Chiari, portal vein, splenic and mesenteric thrombosis)
      • History or other evidence of chronic pulmonary disease associated with functional limitation
      • Thyroid dysfunction not adequately controlled
      • Neutrophil count <1.5 x 10 to 9/L
      • JAK2 exon 12 mutation: PV that lacks the JAK2V617F mutation but is characterized by the exon 12 mutation.
      • Patients cannot meet criteria for post PV or post ET-MF
      • Subjects with any other medical condition, which in the opinion of the investigator would compromise the results of the study by deleterious effects of treatment.
      • No previous exposure to any formulation of pegylated interferon
      • History of major organ transplantation
      • History of uncontrolled severe seizure disorder
      • Inability to give informed written consent
      • Total bilirubin >1.5 x ULN (patients that have an isolated indirect bilirubin that causes total bilirubin to be elevated beyond 1.5 x ULN due to documented Gilbert's syndrome or hemolysis may be included). No detectable PNH (paroxysmal nocturnal hemoglobinuria) clone where tested
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01259856

  Hide Study Locations
Locations
United States, Arizona
Mayo Clinic Recruiting
Scottsdale, Arizona, United States, 85259
Contact: Ruben Mesa, MD    480-301-8335    mesa.ruben@mayo.edu   
Principal Investigator: Ruben Mesa, MD         
United States, California
The Palo Alto Clinic Recruiting
Palo Alto, California, United States, 94301
Contact: David Liebowitz, MD    650-853-2905    liebowd@pamf.org   
Principal Investigator: David Liebowitz, MD         
United States, District of Columbia
Georgetown University Medical Center Recruiting
Washington, District of Columbia, United States, 20007
Contact: Craig Kessler, MD    202-444-8676    kesslerc@gunet.georgetown.edu   
Principal Investigator: Craig Kessler, MD         
United States, Georgia
Emory Hospital Recruiting
Atlanta, Georgia, United States, 30322
Contact: Elliot Winston, MD    404-778-5871    ewinston@emory.edu   
Principal Investigator: Elliot Winston, MD         
United States, Illinois
John H. Stroger Hospital of Cook County Not yet recruiting
Chicago, Illinois, United States, 60612
Contact: Rose Catchatorian, MD    312-864-7257    rcatchator@ccbhs.org   
Principal Investigator: Rose Catchatorian, MD         
University of Illinois at Chicago Not yet recruiting
Chicago, Illinois, United States, 60612
Contact: Damiano Rondelli, MD    312-996-6179    drond@uic.edu   
Principal Investigator: Damiano Rondelli, MD         
United States, Maryland
University of Maryland Not yet recruiting
Baltimore, Maryland, United States, 21201
Contact: Maria Baer, MD    410-328-8708    mbaer@umm.edu   
Principal Investigator: Maria Baer, MD         
United States, New York
Icahn School of Medicine at Mount Sinai Recruiting
New York, New York, United States, 10029
Contact: Ronald Hoffman, MD    212-241-2296    ronald.hoffman@mssm.edu   
Principal Investigator: Ronald Hoffman, MD         
Sub-Investigator: John Mascarenhas, MD         
Weill Cornell Medical College Not yet recruiting
New York, New York, United States, 10065
Contact: Richard Silver, MD    212-746-2856    rtsilver@med.cornell.edu   
Principal Investigator: Richard Silver, MD         
United States, North Carolina
Wake Forest University Baptist Medical Center Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Dmitry Berenzon, MD    336-716-5847    dberenzo@wfubmc.edu   
Principal Investigator: Dmitry Berenzon, MD         
United States, Ohio
Ohio State University Not yet recruiting
Columbus, Ohio, United States, 43210
Contact: Rebecca Klisovic, MD    614-293-4696    rebecca.klisovic@osumc.edu   
Principal Investigator: Rebecca Klisovic, MD         
United States, Pennsylvania
Geisinger Cancer Center Recruiting
Hazelton, Pennsylvania, United States, 18201
Contact: Paul Roda, MD    570-459-2901    Proda@geisinger.edu   
Principal Investigator: Paul Roda, MD         
University of Pennsylvania Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Elizabeth Hexner, MD    215-662-4137    elizabeth.hexner@uphs.upenn.edu   
Principal Investigator: Elizabeth Hexner, MD         
United States, Utah
University of Utah Recruiting
Salt Lake City, Utah, United States, 84132
Contact: Josef Prchal, MD    801-581-4220    josef.prchal@hsc.utah.edu   
Principal Investigator: Josef Prchal, MD         
Belgium
Unicersite Catholique de Louvain Not yet recruiting
Brussels, Belgium
Contact: Laurent Knoops, MD    32-2-7641800    laurent.knoops@uclouvain.be   
Principal Investigator: Laurent Knoops, MD         
France
Hopitaux de Paris Not yet recruiting
Paris, France, 75010
Contact: Jean-Jacques Kiladjian, MD       jean-jacques.kiladjian@sls.aphp.fr   
Principal Investigator: Jean-Jacques Kiladjian, m         
Ireland
Belfast City Hospital Not yet recruiting
Belfast, Ireland, BT9 7AB
Contact: Mary Frances McMullin, MD    02890263733    m.mcmullin@qub.ac.uk   
Principal Investigator: Mary Frances McMullin, MD         
Italy
Ospedale Riuniti de Bergamo Not yet recruiting
Bergamo, Italy
Contact: Alessandro Rambaldi, MD    39-03-5269490    arambaldi@ospedaliriuniti.bergamo.it   
Principal Investigator: Alessandro Rambaldi, MD         
University Of Florence Not yet recruiting
Florence, Italy
Contact: Alessandro Vannucchi, MD    39-055-7947688    a.vannucchi@unifi.it   
Principal Investigator: Alessandro Vannucchi, MD         
Ospedale San Maartino Genova Not yet recruiting
Genova, Italy, 11632
Contact: Francesco Frassoni, MD    39-010-555469    francesco.frassoni@hsanmartino.it   
Principal Investigator: Francesco Frassoni, MD         
San Matteo Hospital Not yet recruiting
Pavia, Italy, 27100
Contact: Gianni Barosi, MD    39-038-2503636    barosig@smateo.pv.it   
Principal Investigator: Gianni Barosi, MD         
Universita Cattolica del Sacro Cuore Not yet recruiting
Rome, Italy, 00168
Contact: Raffaele Landolfi, MD    39-06-30154438    rlandolfi@rm.unicatt.it   
Principal Investigator: Raffaele Landolfi, MD         
Netherlands
VU University Medical Centre, Amsterdam Not yet recruiting
Amsterdam, Netherlands
Contact: Sonja Zweegman, MD, PhD    31-20-4442604    S.Zweegman@vumc.nl   
Principal Investigator: Sonja Zweegman, MD, PhD         
Erasmus Medical Centre Rotterdam Not yet recruiting
Rotterdam, Netherlands
Contact: Peter AW te Boekhorst, MD, PhD    31 10 7033740    p.teboekhorst@erasmusmusmc.nl   
Principal Investigator: Peter AW te Boekhorst, MD, PhD         
Sweden
Sahlgrenska University Hospital Not yet recruiting
Goteborg, Sweden
Contact: Bjorn Andreasson, MD    46-31-3421000    bjorn.andreasson@vgregion.se   
Principal Investigator: Bjorn Andreasson, MD         
Stockholm South Hospita, Sweden Not yet recruiting
Stockholm, Sweden
Contact: Jan Samuelsson, MD, PhD    46-8-6163225    jan.samuelsson@sodersjukhuset.se   
Principal Investigator: Jan Samuelsson, MD, PhD         
United Kingdom
University of Cambridge Not yet recruiting
Cambridge, United Kingdom
Contact: Anthony Green, MD    01-223 762668    arg1000@cam.ac.uk   
Principal Investigator: Anthony Green, MD         
Guy's and St. Thomas' NHS Foundation Trust Not yet recruiting
London, United Kingdom, SE1 7EH
Contact: Claire Harrison, MD    02 71882739    claire.harrison@gstt.sthames.nhs.uk   
Principal Investigator: Claire Harrison, MD         
Sponsors and Collaborators
Ronald Hoffman
Myeloproliferative Disorders-Research Consortium
Roche Pharma AG
QIAGEN Marseille
Investigators
Study Chair: Ronald Hoffman, MD Mount Sinai School of Medicine
Study Chair: Richard Silver, MD Weill Medical College of Cornell University
Study Chair: Claire Harrison, MD Guy's and St Thomas' NHS Foundation Trust
Study Chair: Ruben Mesa, MD Mayo Clinic
Study Chair: Jean-Jacques Kiladjian, MD Hopitaux de Paris
Study Chair: Mary Frances McMullin, MD Belfast City Hospital
  More Information

No publications provided

Responsible Party: Ronald Hoffman, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine
ClinicalTrials.gov Identifier: NCT01259856     History of Changes
Other Study ID Numbers: GCO 09-1300-00002, P01CA108671, MPD-RC 112
Study First Received: December 7, 2010
Last Updated: June 11, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board
Canada: Canadian Regulatory Authority
Italy: European Union Drug Regulatory Authorities
France: European Union Drug Regulatory Authorities
United Kingdom: European Union Drug Regulatory Authorities
Netherlands: European Union Drug Regulatory Authorities
Belgium: European Union Drug Regulatory Authorities
Sweden: European Union Drug Regulatory Authorities

Keywords provided by Mount Sinai School of Medicine:
Polycythemia vera
Essential thrombocythemia
Hydroxyurea
PEGASYS
Pegylated Interferon Alfa-2a

Additional relevant MeSH terms:
Polycythemia
Polycythemia Vera
Thrombocytosis
Thrombocythemia, Essential
Hematologic Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Blood Platelet Disorders
Blood Coagulation Disorders
Hemorrhagic Disorders
Interferons
Hydroxyurea
Interferon-alpha
Peginterferon alfa-2a
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Antisickling Agents
Hematologic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on September 16, 2014